Sirio Pharma Co., Ltd. (SHE:300791)

Sirio Pharma Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Dec 31, 2021	Dec 31, 2020
Operating Revenue	4,426	4,184	3,568	2,493	2,331	2,029
Other Revenue	27.4	27.4	13.91	14.19	38.01	37.42
Revenue	4,454	4,211	3,582	2,507	2,369	2,067
Revenue Growth (YoY)	7.90%	17.56%	42.87%	5.84%	14.62%	30.85%
Cost of Revenue	3,029	2,891	2,498	1,737	1,604	1,405
Gross Profit	1,424	1,320	1,085	770.42	764.94	661.56
Selling, General & Admin	862.03	770.86	628.44	428.27	385.27	306.64
Research & Development	127.82	125.94	110.49	80.72	83.19	64.71
Other Operating Expenses	-28.78	-6.48	-35.8	14.85	14.4	12.82
Operating Expenses	961.55	890.64	708.19	527.83	483.83	387.71
Operating Income	462.78	429.2	376.33	242.59	281.11	273.85
Interest Expense	-21.64	-95.03	-78.48	-42.77	-13.93	-1.8
Interest & Investment Income	2.03	6.89	9.24	34.97	32.18	20.33
Currency Exchange Gain (Loss)	10.86	10.86	20.31	25.49	-18.17	-3.96
Other Non Operating Income (Expenses)	-84.36	-2.87	-1.28	-1.47	-1.25	-1.6
EBT Excluding Unusual Items	369.66	349.05	326.11	258.81	279.96	286.82
Gain (Loss) on Sale of Investments	-28.08	-26.72	-57.67	-1.64	-1.05	3.95
Gain (Loss) on Sale of Assets	0.68	0.24	0.03	-5.51	0.15	-0.01
Asset Writedown	-7.35	-4.41	-0.95	-	-1.86	-1.39
Other Unusual Items	-5.25	-1.51	5.73	-0.15	3.7	22.59
Pretax Income	329.66	316.65	273.26	251.52	280.9	311.96
Income Tax Expense	38.53	34.64	32.97	39.23	49.07	54.6
Earnings From Continuing Operations	291.13	282.02	240.29	212.29	231.83	257.37
Minority Interest in Earnings	54.4	43.04	40.75	-	-	-
Net Income	345.53	325.06	281.04	212.29	231.83	257.37
Net Income to Common	345.53	325.06	281.04	212.29	231.83	257.37
Net Income Growth	2.93%	15.66%	32.39%	-8.43%	-9.92%	80.58%
Shares Outstanding (Basic)	305	304	305	304	304	304
Shares Outstanding (Diluted)	305	304	305	307	322	306
Shares Change (YoY)	0.12%	-0.36%	-0.82%	-4.47%	5.00%	23.77%
EPS (Basic)	1.13	1.07	0.92	0.70	0.76	0.85
EPS (Diluted)	1.13	1.07	0.92	0.69	0.72	0.84
EPS Growth	2.81%	16.08%	33.48%	-4.15%	-14.21%	45.89%
Free Cash Flow	206.27	154.84	-65.62	151.17	-183.31	96.43
Free Cash Flow Per Share	0.68	0.51	-0.21	0.49	-0.57	0.32
Dividend Per Share	0.500	0.500	0.651	0.207	0.237	0.237
Dividend Growth	-23.18%	-23.18%	214.29%	-12.50%	-	200.00%
Gross Margin	31.98%	31.34%	30.28%	30.73%	32.29%	32.01%
Operating Margin	10.39%	10.19%	10.51%	9.68%	11.87%	13.25%
Profit Margin	7.76%	7.72%	7.85%	8.47%	9.79%	12.45%
Free Cash Flow Margin	4.63%	3.68%	-1.83%	6.03%	-7.74%	4.67%
EBITDA	617.17	612.03	597.06	366.95	379.29	353.57
EBITDA Margin	13.86%	14.53%	16.67%	14.64%	16.01%	17.11%
D&A For EBITDA	154.4	182.83	220.73	124.36	98.18	79.72
EBIT	462.78	429.2	376.33	242.59	281.11	273.85
EBIT Margin	10.39%	10.19%	10.51%	9.68%	11.87%	13.25%
Effective Tax Rate	11.69%	10.94%	12.06%	15.60%	17.47%	17.50%
Revenue as Reported	1,163	4,211	3,582	2,507	2,369	2,067
Advertising Expenses	-	12.17	7.8	11.73	31.9	11.26

Source: S&P Global Market Intelligence. Standard template. Financial Sources.